Heme biosynthesis and degradation: What happens when it goes haywire?

Heme Biology: The Secret Life of Heme in Regulating Diverse Biological Processes

Volumn , Issue , 2011, Pages 7-32

  Zhang, Li ^a   Sessoms, Rebekah ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970966423     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814287937_0002     Document Type: Chapter

References (134)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. 2009. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In The metabolic and Molecular Bases of Inherited Disease, eds. CR. Scriver, AL Beaudt. WS Sly, D Valle, C Barton, KW Kinzler, B Vogelstein, Chapter 124. pp. 1-53. New York: The McGraw-Hill Companies, Inc.
2. Ortiz de Montellano PR. 2009. Hemes in Biology. In Wiley Encyclopedia of Chemical Biology, pp. 240-249. West Sussex: John Wriley & Sons. Ltd.
3. Sassa S, Kappas A. 1995. Disorders of heme production and catabolism. In Blood: Principles and Practice of Hematology, eds. R.I Handin, SE Lux, TP Stossel, pp. 1473-1523. Philadephia: J.B. Lippincott Company.
4. Labbe-Bois R, Labbe P. 1990. Tetrapyrrole and heme biosynthesis in the yeast Sacchromyces cerevisiae. In Biosynthesis of Heme and Cholorophylls, ed. HA Dailey, pp. 235-285. New York: Green Pub. Associates and Wiley-Interscience.
5. Bishop DF. 1990. Two different genes encode delta-aminolevulinate synthase in humans: Nucleotide sequences of cDNAs for the housekeeping and ery-throid genes. Nucleic Acids Res 18: 7187-7188.
6. Bishop DF, Henderson AS, Astrin KH. 1990. Human delta-aminolevulinate synthase: Assignment of the housekeeping gene and the erythroid-specific gene to the X chromosome. Genomics 7: 207-214.
7. Potluri VR, Astrin KH, Wetmur JG, Bishop DF, Desnick RJ. 1987. Human delta-aminolevulinate dehydratase: Chromosomal localization to 9q34 by in situ hybridization. Hum Genet 76: 236-239.
8. Kaya AH, Plewinska M, Wong DM, Desnick RJ, Wetmur JG. 1994. Human delta-aminolevulinate dehydratase (ALAD) gene: Structure and alternative splicing of the erythroid and housekeeping mRNAs. Genomics 19: 242-248.
9. Sassa S, Granick S, Bickers DR, Levere RD, Kappas A. 1973. Studies on the inheritance of human erythrocyte delta-aminolevulinate dehydratase and uroporphyrinogen synthetase. Enzyme 16: 326-333.
10. Meisler M, Wanner L, Eddy RE, Shows TB. 1980. The UPS locus encoding uroporphyrinogen I synthase is located on human chromosome 11. Biochem Biophys Res Commun 95: 170-176.
11. Chretien S, Dubart A, Beaupain D, Raich N, Grandchamp B, Rosa J, Goossens M, Romeo PH. 1988. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sci USA 85: 6-10.
12. Xu W, Kozak CA, Desnick RJ. 1995. Uroporphyrinogen-1 II synthase: molecular cloning, nucleotide sequence, expression of a mouse full-length cDNA, and its localization on mouse chromosome 7. Genomics ‘26: 556-562.
13. de Verneuil II, Grandchamp B, Foubert C, Weil D, N’Guyen VC, Gross MS, Sassa S, Nordmann Y. 1984. Assignment of the gene for uroporphyrinogen decarboxylase to human chromosome I by somatic cell hybridization and specific enzyme immunoassay. Hum Genet 66: 202-205.
14. Dubart A, Mattei MG, Raich N, Beaupain D, Romeo PH, Mattei JF, Goossens M. 1986. Assignment of human uroporphyrinogen decarboxylase (URO-D) to the p34 band of chromosome 1. Hum Genet 73: 277-279.
15. Cacheux V, Martasek P, Fougerousse F, Delfau MH, Druart L, Tachdjian G, Grandchamp B. 1994. Localization of the human coproporphyrinogen oxidase gene to chromosome band 3ql2. Hum Genet 94: 557-559.
16. Takahashi S, Taketani S, Akasaka JE, Kobayashi A, Hayashi N, Yamamoto M, Nagai T. 1998. Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Blood 92: 3436-3444.
17. Taketani S, Inazawa J, Abe T, Furukawa T, Kohno H, Tokunaga R, Nishimura K, Inokuchi H. 1995. The human protoporphyrinogen oxidase gene (PPOX): Organization and location to chromosome 1. Genomics 29: 698-703.
18. Roberts AG, Whatley SD, Daniels J, Holmans P, Fenton I, Owen MJ, Thompson P, Long C, Elder GH. 1995. Partial characterization and assignment of the gene for protoporphyrinogen oxidase and variegate porphyria to human chromosome lq23. Hum Mol Genet 4: 2387-2390.
19. Whitcombe DM, Carter NP, Albertson DG, Smith SJ, Rhodes DA, Cox TM. 1991. Assignment of the human ferrochelatase gene (FECH) and a locus for protoporphyria to chromosome 18q22. Genomics 11: 1152-1154.
20. Taketani S, Inazawa J, Nakahashi Y, Abe T, Tokunaga R. 1992. Structure of the human ferrochelatase gene. Exon/intron gene organization and location of the gene to chromosome 18. Eur J Biochem 205: 217-222.
21. Mattoon J, Lancashire W, Sanders H, Carvajal E, Malamud D, Braz G, Panek A. 1979. Oxygen and catabolite regulation of hemoprotein biosynthesis in the yeast Saccharomyces cerevisiae. In Biosynthesis of Heme and Cholorophylls, ed. WrJ Caughey, pp. 421-435. New York: Academic Press.
22. Hon T, Dodd A, Dirmeier R, Gorman N, Sinclair PR, Zhang L, Poyton RO. 2003. A mechanism of oxygen sensing in yeast: Multiple oxygen-responsive steps in the heme biosynthetic pathway affect Hapl activity. J Biol Chem 278: 50771-50780.
23. Granick S, Sassa S. 1971. Aminolevulinic acid synthetase and the control of heme and chlorophyll synthesis. In Metabolic Regulation, ed. JH Vogel, pp. 77. New York: Academic Press.
24. Sassa S, Kappas A. 1981. Genetic, metabolic, and biochemical aspects of the porphyrias. In Adv Hum Genet, pp. 121-231.
25. De Matteis F, Abbritti G, Gibbs AH. 1973. Decreased liver activity of por-phyrin-metal chelatase in hepatic porphyria caused by 3,5-diet hoxycarbonyl- 1.4-dihydrocollidine. Studies in rats and mice. Biochem J 134: 717-727.
26. De Matteis F, Gibbs A. 1972. Stimulation of liver 5-aminolaevulinate synthetase by drugs and its relevance to drug-induced accumulation of cytochrome. Studies with phenylbutazone and 3,5-diet hoxycarbonyl- 1.4-dihydrocollidine. Biochem J 126: 1149-1160.
27. Whiting MJ, Granick S. 1976. Delta-Aminolevulinic acid synthase from chick embryo liver mitochondria. I. Purification and some properties. J Biol Chem 251: 1340-1346.
28. Sinclair PR, Granick S. 1975. Heme control on the synthesis of delta-aminolevulinic acid synthetase in cultured chick embryo liver cells..4nn N Y Acad Sci 244: 509-520.
29. Sassa S, Kappas A. 1977. Induction of aminolevulinate synthase and porphyrins in cultured liver cells maintained in chemically defined medium. Permissive effects of hormones on induction process. J Biol Chem 252: 2428-2436.
30. Granick S. 1966. The induction in vitro of the synthesis of delta-aminolevulinic acid synthetase in chemical porphyria: A response to certain drugs, sex hormones, and foreign chemicals. J Biol Chem 241: 1359-1375.
31. Granick S, Urata G. 1963. Increase in activity of alpha-aminolevulinic acid synthetase in liver mitochondria induced by feeding of 3,5-dicarbethoxy-l,4-dihydrocollidine. J Biol Chem 238: 821-827.
32. Hutton JJ. Gross SR. 1970. Chemical induction of hepatic porphyria in inbred strains of mice. Arch Biochem Biophys 141: 284-292.
33. Sassa S, Granick S. 1970. Induction of 5-aminolevulinic acid synthetase in chick embryo liver cells in cluture. Proc Natl Acad Sci USA 67: 517-522.
34. Tyrrell DL, Marks GS. 1972. Drug-induced porphyrin biosynthesis. V. Effect of protohemin on the transcriptional and post-transcriptional phases of aminolevulinic acid synthetase induction. Biochem Pharmacol 21: 2077-2093.
35. Lathrop JT, Timko MP. 1993. Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science 259: 522-525.
36. Munakata H, Sun JY, Yoshida K, Nakatani T, Honda E, Hayakawa S, Furuyama K, Hayashi N. 2004. Role of the heme regulatory motif in the heme-mediated inhibition of mitochondrial import of 5-aminolcvulinatc synthase. J Biochem 136: 233-238.
37. Surinya KH, Cox TC, May HK. 1997. TVanscriptional regulation of the human erythroid 5-aminolcvulinatc synthase gene. Identification of promoter elements and role of regulatory proteins. J Mol Chem 272: 26585-26591.
38. Granick JL, Sassa S. 1978. Hcmin control of heme biosynthesis in mouse I'Viend virus-transformed erythroleukemia cells in culture. J Mol Chem 253: 5402-5406.
39. Rutherford T, Thompson GG, Moore Mil. 1979. Heme biosynthesis in I'Viend erythroleukemia cells: Control by ferrochelatase. Proc Natl Acad Sci U S A 76: 833-836.
40. Fisher JVV. 1997. Erythropoietin: Physiologic and pharmacologic aspects. Proc Soc Exp Mol Med 216: 358 369.
41. Meyer UA, Schuurmans MM, Lindberg RL. 1968. Acute porphyrias: Pathogenesis of neurological manifestations. Semin Liver D is 18: 43-52.
42. Moore MR. 1990. Historical introduction to porphyrins and porphyrias. In lliosynthcsis of Heme and Cholorophylls, ed. HA Dailey, pp. 1-54. New York: Green Pub. Associates and Wilcy-Intcraciencc.
43. Nordmann Y, Dcybach J-C. 1990. Human hereditary porphyrias. In lliosynthcsis of Heme and Cholorophylls, cd. HA Dailey, pp. 491-541. New York: Green Pub. Associates and Wiley-Intersdence.
44. Kappas A, Sassa S, Galbraith HA, Nordmann Y. 1955. The porphyrias. In The Metabolic and Molecular liases of Inherited Disease, cd. CH. Scriver, AI, Heaudt, YVS Sly, D Valle, pp. 2103-2160. New York: Ihe McGraw-Hill Companies, Inc.
45. May A, Hishop DF. 1998. Ihe molecular biology and pyridoxinc responsiveness of X-linked sideroblastic anaemia. Hacmalologica 83: 56-70.
46. Cotter PD, May A, Li L, Al-Sabah AI, Kitzsimons KJ, Cazzola M, Hishop DF. 1999. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: Increased pyridoxinc responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis, lilood 93: 1757-1769.
47. Cotter PD, May A, Kitzsimons KJ, Houston T, Woodcock HK, al-Sabah AI, Wong L, Hishop DK. 1995. I.atc-onsct X-linked sideroblastic anemia. Misscnsc mutations in the erythroid dclta-aminolcvulinatc synthase (ALAS2) gene in two pyridoxinc-responsivc patients initially diagnosed with acqtiired refractory anemia and ringed sidcroblasts. J Clin Invest 96: 2090-2096.
48. Cotter PD, Baumann M, Hishop DK. 1992. Knzymatic defect in “X-linked” sideroblastic anemia: molecular evidence for erythroid dclta-aminolcvulinatc synthase deficiency. I’roc Natl Acad Sci U S A 89: 4028 4032.
49. Cotter PD, Ruckriagcl DL, Hishop DK. 1991. X-linked sidcroblastic anemia: Identification of the mutation in the crythroid-spccific dclta-aminolcvulinatc synthase gene (ALAS2) in the original family described by Cooley. Blood 81: 3915-3924.
50. Pradcs E, Cham bon C, Dailey TA, Dailey HA, Hricrc J, Grandchamp H. 1995. A new mutation of the ALAS2 gene in a large family with X-linkcxl sidcroblastic anemia. Hum Genet 95: 424-428.
51. Edgar AJ, Losowsky MS, Noble JS, Wickramasinghc SN. 1997. Identification of an argininc152 to histidine substitution in the erythroid 5-aminolacvulinate synthetase gene in a large pedigree with X-linkcd hereditary sidcroblastic anaemia, Eur J Haematol 58: 14.
52. Shoolingin-Jordan PM, Spcncer PMS, Erskinc PE. Cheung KM, Cooper JH, Norton EH. 2002. 5-Aminolacvulinic acid dehydratase: Metals, mutants and mechanism, liiochcm Soc I Vans 30: 581-590.
53. Poh-Fitzpatrick MH Porphyrias: Photosensitivity and phototherapy. Methods Enzymol 319: 485-493.
54. Dcsnick RJ, Glass IA, Xu W, Solis C, Astrin KH. 1998. Molecular gcnctics of congenital crythropoictic porphyria. Semin Liver 18: 77-84.
55. Poh-Fitzpatrick MH, Wang X, Anderson KE, Hloomcr J, Holwcll H, Lichtin AE. 2002. Erythropoietic protoporphyria: Altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient hct-croallclic for fcrrochclatasc gene mutations. J Am Acad Dermatol 46: 861-866.
56. Elder CH. 1998. Porphyria cutanca tarda. Semin Liver Dis 18: 67-75.
57. Bulat V, Iugovic L, Situm M, Huljan M, Hradic L. 2007. Porphyria cutanca tarda as the most common porphyria. Acta Dcrmatovcnerol Croat 15: 251-263.
58. Lambrccht RW, l'hapar M, Honkovsky HL. 2007. Gcnctic aspects of por-phyria cutanca tarda. Semin Liver Dis 27: 99-108.
59. Fargion S, Pipcrno A, Cappcllini MD, Sampictro M, Fracanzani AL, Romano It, Caldardli R, Marcclli R, Vocchi L, Fiorelli G. 1992. Hepatitis C virus and porphyria cutanea tarda: Evidcncc of a strong association. Hepatology 16: 1322-1326.
60. Hcrrcro C, Viccntc A, Hrugucra M, Errilla MG, Harrera JM, Vidal J, Ifcrcs J, Mascaro JM, Rodes J. 1993. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? l.ancel 311: 788 799.
61. Chuang TY, Hrashcar R, I-cwis C. 1991. Porphyria cutanca tarda and hepatitis C virus: A case-control study and mcta-analysis of the literature. J Am Acad Dermatol 41:31-36.
62. Egger NG, Gocger DE, Miskovsky EP, Weinman SA, Payne DA, Anderson KE. 1999. Multiple risk factors including IIFE mutations in porphyria cutanca tarda. Gastroenterology 116: Starts at A1206.
63. Wissd PS, Sordillo I’, Anderson KE, Kappas A, Sassa S, Savillo III.. 1987. Porphyria cutanca tarda associated with the acquired immune dcficicncy syndrome. Am J Hcmatol: 107-113.
64. Cohen PH. 1991. Porphyria cutanca tarda in human immunodeficiency virus-seropositive men: Case report and literature review. J Acquir Immune Dcfie Syndr. 1: 1112-1127.
65. Taljaard JJ, Shanlcy HC, Deppe WM, Joubcrt SM. 1972. Prophyrin metabolism in experimental hepatic siderosis in the rat. II. Combined effect of iron overload and hcxachlorobcmcnc. Hr J Haematol 23: 513-519.
66. Laljaard JJ, Shanlcy HC, Deppe WM, Joubcrt SM. 1972. Porphyrin metabolism in experimental hepatic siderosis in the rat. III. Eficct of iron overload and hcxachlorobcnzenc on liver hacm biosynthesis. Hr J Haematol 23: 587-593.
67. Moore AW, 3rd, Coke JM. 2000. Acute porphyric disorders. Oral Surg Oral Med Oral I’athol Oral Radiol Endod 90: 257-262.
68. Sams II, KiripoLsky MG, Hhat L, Stricklin CP. 2001. Porphyria cutanca tarda, hepatitis C, alcoholism, and hemochromatosis: A case report and review of the literature. Cutis 73: 188-190.
69. Kostlcr E, Wollina IJ. 2005. Iherapy of porphyria cutanca tarda. Expert Opin Hharmacothcr 6: 377-383.
70. Sarkany I. 2001. "The management of porphyria cutanca tarda. CHn Exp Dermatol 26: 225-232.
71. Elder CH. 1991. Alcohol intake and porphyria cutanca tarda. Clin Dermatol 17: 131-136.
72. Moran-Jimcncz MJ, Gcd C, Homana M, Enriquez De Salamanca R, TaTcb A, Topi G, D’Alcssandro L, dc Vcmcuil II. 1996. Uroporphyrinogen decar-boxylasc: Complete human gene sequence and molecular study of three families with hcpatocrythropoictic porphyria. Am J Hum Genet 58: 712-721.
73. Kordac V. 1972. Frequency of occurrence of hepatocellular carcinoma in jxaticnts with porphyria cutanca tarda in long-term follow-up. N coplasma 19: 135-139.
74. Cortes JM, Oliva II, Paradinas FJ, IIcmandcz-Guio C. 1980. Ihe pathology of the liver in porphyria cutanca tarda. H istopathology 1: 171-485.
75. Pischik E, Kauppincn R. 2009. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-lc-grand) 55: 72-83.
76. Herrick A I., McColl KE. 2005. Acute intermittent porphyria. Best I’ract Res Clin Gastroenterol 19: 235-219.
77. Kauppincn R, Mustajoki I’. 1912. Prognosis of acutc porphyria: Occurrcncc of acutc attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 71: 1-13.
78. Bylcsjo I, Wikberg A, Andensson C. 2009. Clinical aspccLs of acutc intermittent porphyria in northern Sweden: A population-based study. Scand J Clin l.ab Invest 69: 612-618.
79. Kochar DK, Pal M, Kochar SK, Vyas A, Kochar A, Bindal D, Agrawal RP. 2007. Acutc intermittent porphyria presenting with neurological emergency: Review of six cases. Neurol India 55: 413-415.
80. Palmer KM. 2006. Abdominal pain due to acutc intermittent porphyria: When is the sound of hoof-bcats not horses, but zebras? A ease report. Dimens Crit Care Nurs 25: 103-109.
81. Waldenstrom J. 1957. Ihe porphyrias as inborn errors of metabolism. Am J Med 22: 758-773.
82. Goldberg A. 1959. Acutc intermittent porphyria: A study of 50 cases. Q J Med. 28: 183-209.
83. Stein JA, Tschudy DP. 1970. Acutc intermittent porphyria. A clinical and biochcmical study of 46 patients. Medicine 49: 1-16.
84. Asselbergs FW, Krcmcr Hovinga TK, Bouwsma C, van Ingen J. 2009. Acutc intermittent porphyria as a cause of respiratory failure: Case report. Am J Crit Care 18: 180, 78-79.
85. Granick S, Van Den Schrcieck IIG. 1955. Porphobilinogen and dclta-aminolcvulinic acid in acutc porphyria. Pros Soc Kip Biol Med 88: Starts at 270.
86. Robert TL, Varclla L, Mcguid MM. 1991. Nutrition management of acutc intermittent porphyria. Nutrition 10: 551-555; quiz 6 7.
87. Atamna II. 2001. Heme, iron, and the mitochondrial decay of ageing. Ageing lies Rev 3: 303-318.
88. Zhu Y, Hon T, Ye W, Zhang I,. 2002. Heme dcficicncy interferes with the Ras-mitogcn-activatcd protein kinase signaling pathway and expression of a subset of neuronal genes. Cell Growth Differ 13: 131-439.
89. Sengupta A, Hon T, Zhang L. 2005. Hcmc deficiency suppresses the expression of key neuronal genes and causes neuronal cell death. Drain Res Mol Drain Res 137: 23-30.
90. Dwyer HK, Smith MA, Richardson SI., Perry G, Zhu X. 2009. Down-rcgulation of aminolevulinatc synthase, the rate-limiting enzyme for hcmc biosynthesis in Alzheimer s disease. Arcurosct Lett 460: 180-184.
91. Lifcnhuncn R, Marver IIS, Schmid R. 1969. Microsomal hcmc oxygenase. Characterization of the enzyme. J liiol Chem 244: 6388-6391.
92. Chowdhuiy J, WolkolT AW, Chowdhury N, Arias IM. 2009. Hereditary Jaundice and Disorders of Bilirubin Metabolism. In The Metabolic and Molecular liases of Inherited Disease, eds. CR Scrivcr, AI. Bcaudt, WS Sly, D Valle, C Harton, KW Kinzler, H Vogelstcin. Chapter 125, pp. 1-90. New York: The McGraw-Hill Companies, Inc.
93. Li C, Stocker R. 2009. Hcmc oxygenase and iron: I rom bactcria to humans. Redox Rep 14: 95-101.
94. Jackson AH, Kenner W. 1968. Recent developments in porphyrin chemistry. In Porphyrins and related compounds, pp. 5: Ixmdon: Academic Press.
95. Hissell DM, Hammakcr L, Schmid R. 1972. Liver sinusoidal cells. Identification of a Subpopulation for Erythrocyte Catabolism. J Cell liiol 51: 107-119.
96. Maincs MD, Trakshcl GM, Kutty RK. 1986. Characterization of two constitutive forms of rat liver microsomal hcmc oxygenase. Only one molecular species of the enzyme is inducible. J liiol Chem 261:111-119.
97. McCoubrcy WK., Huang TJ, Maincs MD. 1997. Hcmc oxygcnasc-2 is a hemoprotcin and binds hcmc through hcmc regulatory motifs that arc not involved in hcmc catalysis. J liiol Chem 272: 12568-12571.
98. Wagcncr FA, Volk IID, Willis D, Abraham NG, Soares MP, Adcma GJ 2003. Different faccs of the hcmc-heme oxygenase system in inflammation. Pharmacol Rev 55: 551-571.
99. Sikorski KM, Hock T, Hill-Kapturcyak N, Agarwal A. 2001. Ihe story so fan Molccular regulation of the hcmc oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol 286: K425-F441.
100. Schipper ILM. 2001. Hcmc oxygenase expression in human central nervous system disorders. Free Radic liiol Med: 1995-2011.
101. Schipper HM, Chcrtkow II, Mchindatc K, Irankcl D, Melmcd C, Hcrgman II. 2000. Evaluation of hcmc oxygenase-1 as a systemic biological marker of sporadic AD. Neurology 51: 1297-1301.
102. Schipper HM, Cissc S, Stopa EG. 1995. Expression of hcmc oxygcnasc-1 in the scncscent and Akhcimcr-discased brain..Inn Neurol 37: 758-768.
103. Sassa S, Kappas A, Bernstein SE, Alvares AP. 1979. Hcmc biosynthesis arid drug metabolism in mice with hereditary hcmolytic anemia. Heme oxygenase induction as an adaptive response for maintaining cytochromc P-450 in chronic hemolysis. J liiol Chem 251: 729-735.
104. Irnmenschuh S, Ramadori G. 2000. Gene regulation of hcmc oxygcnasc-1 as a thcrapcutic target, liiochcm Pharmacol (H): 1121-1128.
105. Lee PJ, Jiang BH, Chin BY, Iyer NV, A lam J, Scmcnza CL, Choi AM. 1997. Hypoxia-induciblc factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J liiol Chem 272: 5375-5381.
106. Takahashi S, Takahashi Y, Yoshimi T, Miura T. 1998. Oxygen tension regulates heme oxygcnasc-1 gene expression in mammalian ccll lines. Cell Biochem l-'uncl 16: 183-193.
107. Mottcrlini I, Korcsti I, Bassi I., Calabrese C. 2000. Endothelial hcmc oxygenase-1 induction by hypoxia. Modulation by inducible nitric-oxidc synthase and S-nitrosothiols. J Biol Chem 275: 13613-13620.
108. Yang ZZ, Zou AI. 2001. I'ranscriptional regulation of hcmc oxygenases by II IK-1 alpha in renal medullary interstitial cdls. Am J Physiol Renal Physiol 281: F900-F908.
109. Shibahara S, Nakayama M, Kilamuro T, Udorio-lujimori I, Takahashi K. 2003. Repression of hcmc oxygcnasc-1 expression as a defense strategy in humans. F.xp liiol Med (Maywood) 228: 472-473.
110. Kacimi R, Chentoufi J, Honbo N, Iong CS, Karlincr JS. 2000. Hypoxia differentially regulates stress proteins in cultured cardiomyocytcs: Hole of the stress-activated kinase signaling cascade, and relation to cytoprotoction. Cardiovase Res ¦16: 139-150.
111. Kitamuro T, Ikkahashi K, Ogawa K, IJdono-Kujimari I, Takcda K, Kuruyama K, Nakayama M, Sun J, Fuji La II, Hida W, llattori T, Shirato K, Igarashi K, Shibahara S. 2003. I Inch 1 functions as a hypoxia-inducible repressor for the hcmc oxygcnasc-1 gene in human cells. J liiol Chem 278: 9125-9133.
112. Vitek L, Ostrow JD. 2009. Bilirubin chemistry and metabolism; harmful and protective aspccts. Carr Pharm Des 15: 2869-2883.
113. Berk PD, Howe It.IJ, Bloomer JR, Berlin NI. 1969. Studies of bilirubin kinetics in normal adults. J Clin Invest 18: 2176-2190.
114. London IM, West R, Shemin D. 1919. On the origin of bile pigment in normal man. J. liiol Chem 184: 351-358.
115. Gordon K, Corcsky CA,. 1976. The isolation and characterization of bilirubin diglucuronidc, the major bilirubin conjugate in dog and human bile. Biochem J 155: 477-486.
116. Bosma PJ, Scppcn J, Coldhoorn B, Bakkcr C, Oudc Klfcrink P, Chowdhury J, Chowdhury NR, Jansen PL. 1991. Bilirubin UDP-glu-curonosyltransfcrasc l is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269: 17960-17961.
117. Ollingcr I, Wang I, Yamashita K, Wcgicl B, Thomas M, Margreiter I, Bach PH. 2007. 'Therapeutic applications of bilirubin and bilivcrdin in transplantation. Anlioxid Redox Signal 9: 2175-2185.
118. Ollingcr R, Yamashita K, Bilban M, Krat A, Koglcr P, Thomas M, Csimadia K, IJshcva A, Margrcitcr R, Bach KH. 2007. Bilirubin and bilivcrdin treatment of atherosclerotic diseases. Cell Cycle 6: 39-43.
119. Stockcr It, Yamamoto Y, McDonagh AF, Glazer AN, Ames UN. 1987. Bilirubin is an antioxidant of possible physiological importance. Sciencc 235: 1013-1046.
120. Halliwell B, Gutteridgc JM. 1990. '1'hc antioxidants of human extracellular fluids. Arch Biochem Biophys 280: 1-8.
121. Dennery PA, McDonagh AF, Spitz DR, Itodgers PA, Stevenson DK. 1995. Hyperbilirubinemia results in reduced oxidative injury in neonatal Chinn rats exposed to hyperoxia. Free lladic Biol Med 19: 395-401.
122. Kirk JM. 2008. Neonatal jaundice: A critical review of the role and practice of bilirubin analysis. Inn Clin lliochcm 45: 452-462.
123. Maiscls MJ, McDonagh AF. 2008. Phototherapy for neonatal jaundice. AF Engl J Med 358: 920-928.
124. Kaplan M, Hammerman C. 2005. Understanding severe hyperbilirubinemia and preventing kcmicterus: adjuncts in the interpretation of neonatal serum bilirubin. Clin Chim Acta 356: 9-21.
125. Gourlcy GR. 1997. Bilirubin metabolism and kcmicterus. Adv Pediatr 44: 173-229.
126. Scharschmidt BF, Gollari JL. 1979. Current concepts of bilirubin metabolism and hereditary hyperbilirubinemia. Prog Liver Dis 6: 187-212.
127. Wolkoff AW. 1983. Inheritable disorders manifested by conjugated hyperbilirubinemia. Semin Liver Dis 3: 65-72.
128. Huang CS. 2005. Molecular genetics of unconjugatcd hyperbilirubinemia in 'lluwancsc. J lliomcd Sci 12: 145-450.
129. Jansen PL. 1999. Diagnosis and management of Crigler-Najjar syndrome. Eur J Pcdialr 158 Suppl 2: S89-S91.
130. Sampictro M, lolascon A. 1999. Molecular pathology of Crigler-Najjar type I and II and Gilbert’s syndromes. llacmalologica M: 150-157.
131. Ritter JK, Yealman MT, Ferreira P, Owens IS. 1992. Identification of a genetic alteration in the axle for bilirubin UDP-ghieuronasyltransferase in the UGTl gene complex of a Crigler-Najjar type I patient. J Clin Invest 90: 150-155.
132. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oudc Klferink RP, Jansen PL, Chowdhury JR. 1992. Scquencc of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransfcrasc gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. llcpalology 15: 941-917.
133. Zimniak P. 1913. Dubin-Johnson and Rotor syndromes: Molccular basis and pathogenesis. Semin Liver Dis 13: 248-260.
134. Luketic VA, Shiftman ML. 2001. Benign recurrent intrahcpatic cholcstasis. Clin Liver Dis 8: 133-149